Dr. Young has over 30 years of pharmaceutical research, drug development, and corporate experience. He is currently a founder, CEO and board member of Processa Pharmaceuticals. He has had multiple successful exits, including Questcor Pharmaceuticals and GloboMax. Dr. Young has met more than 100 times with the FDA on more than 50 drug products, and was previously a Tenured Associate Professor at the School of Pharmacy, University of Maryland.
Dr. Young received his B.S. in Physiology from the University of California at Berkeley, his M.S. in Medical Physics from the University of Wisconsin at Madison, and his Pharm.D. - Ph.D. with emphasis in Pharmacokinetics and Pharmaceutical Sciences from the University of Southern California.
Alan J. Levy, Ph.D.
Dr. Levy is a life science pioneer with a long record of success as a technical innovator, founder, CEO, chairman, venture partner and advisor. He has lead companies such as Chrono Therapeutics, Incline Therapeutics, Northstar Neuroscience and Heartstream. Dr. Levy also held various positions within the Johnson & Johnson company, including Vice President of Research and New Business Development and a member of the Board of Directors of Ethicon, a division of Johnson & Johnson.
Dr. Levy earned a B.S. in Chemistry from the City University of New York and a Ph.D. in Organic Chemistry from Purdue University.
ROBERT BOOTH, PH.D.
Dr. Booth has spent more than 30 years in the biopharmaceutical industry, most recently as founder and chief executive officer of Virobay Inc. He is also an Adjunct Professor in the School of Medicine at Stanford. Additionally, he has served as operating partner and senior advisor at TPG Biotech. Prior to Virobay, Dr. Booth was the chief scientific officer at Celera Genomics, where he was responsible for all discovery and development activities. Dr. Booth conceived and initiated the BTK inhibitor program that was ultimately licensed to Pharmacyclics and from which Imbruvica was developed and approved. Dr. Booth served on the board of directors of Pharmacyclics until its acquisition by AbbVie. Prior to Celera, Dr. Booth was senior vice president for Roche in Palo Alto, California, where he was a member of the global research management team and the business development committee, which oversaw licensing opportunities.
Dr. Booth received his BSc and PhD in biochemistry from the University of London.
IJLAL BABAR, M.D.
Dr. Babar is a Pulmonologist who treats patients with Acute Respiratory Distress Syndrome (ARDS). Dr. Babar received his medical degree from Aga Kahn University and completed his training at University of Arizona. He came to Ocean Springs, Mississippi from the University of Arizona in 2003, where he held an academic position of Assistant Professor of Medicine. Dr. Babar is board certified in Pulmonology, Critical Care and Sleep Medicine. He is the medical director of pulmonary critical care and pulmonary hypertension at Singing River Hospital system.
LEONARD HAYFLICK, PH.D.
Dr. Leonard Hayflick discovered the doubling limit of normal human cells, its' interpretation as aging or senescence, the immortality of cancer cells, and normal cell memory. He also invented the normal human cell strain WI-38 used world-wide to prepare most human virus vaccines. He discovered Mycoplasma pneumoniae, (the smallest free-living microorganism) to be the cause in humans of Primary Atypical Pneumonia (Walking Pneumonia). He is a Professor of Anatomy at the UCSF School of Medicine and founding member of the Council of the National Institute on Aging, NIH.
Dr. Hayflick received his PhD from University of Pennsylvania in Medical Microbiology.
Contact us today to learn more about GEn1E Lifesciences